Key Points
- Mark Goldsmith sold 15,394 shares of Revolution Medicines at an average price of $76.82 on Dec. 16, generating about $1.18M and cutting his ownership by 6.21% to 232,469 shares valued at ~$17.86M.
- Revolution Medicines reported quarterly EPS of ($1.61), missing estimates of ($1.39), and the stock trades near $76 with a market cap of ~$14.7B and a 12‑month range of $29.17–$81.49.
- Analysts have an overall Buy consensus with an average price target of $78.50, and institutional investors hold roughly 94.34% of the shares.
Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) CFO Jack Anders sold 3,104 shares of the firm's stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $77.09, for a total value of $239,287.36. Following the completion of the sale, the chief financial officer directly owned 108,065 shares of the company's stock, valued at $8,330,730.85. This represents a 2.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Revolution Medicines Stock Down 1.0%
Revolution Medicines stock opened at $75.96 on Friday. The stock's 50 day moving average price is $66.12 and its 200 day moving average price is $48.95. Revolution Medicines, Inc. has a 1-year low of $29.17 and a 1-year high of $81.49. The company has a market cap of $14.68 billion, a PE ratio of -14.69 and a beta of 0.96. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.05 and a quick ratio of 8.05.
Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its earnings results on Wednesday, November 5th. The company reported ($1.61) EPS for the quarter, missing analysts' consensus estimates of ($1.39) by ($0.22). During the same quarter in the prior year, the business earned ($0.94) earnings per share. On average, sell-side analysts predict that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.
Hedge Funds Weigh In On Revolution Medicines
Several hedge funds and other institutional investors have recently made changes to their positions in RVMD. GAMMA Investing LLC grew its stake in Revolution Medicines by 45.1% in the third quarter. GAMMA Investing LLC now owns 837 shares of the company's stock worth $39,000 after purchasing an additional 260 shares in the last quarter. Public Employees Retirement System of Ohio raised its stake in Revolution Medicines by 0.6% during the third quarter. Public Employees Retirement System of Ohio now owns 54,143 shares of the company's stock valued at $2,528,000 after buying an additional 336 shares in the last quarter. California State Teachers Retirement System lifted its holdings in Revolution Medicines by 0.3% during the 2nd quarter. California State Teachers Retirement System now owns 140,077 shares of the company's stock worth $5,153,000 after buying an additional 437 shares during the last quarter. CWM LLC lifted its holdings in Revolution Medicines by 171.3% during the 2nd quarter. CWM LLC now owns 917 shares of the company's stock worth $34,000 after buying an additional 579 shares during the last quarter. Finally, Arizona State Retirement System grew its position in shares of Revolution Medicines by 1.6% in the 3rd quarter. Arizona State Retirement System now owns 41,299 shares of the company's stock worth $1,929,000 after acquiring an additional 646 shares in the last quarter. Institutional investors and hedge funds own 94.34% of the company's stock.
Analyst Ratings Changes
A number of research firms recently commented on RVMD. Truist Financial started coverage on shares of Revolution Medicines in a report on Friday, September 5th. They set a "buy" rating and a $99.00 price objective on the stock. National Bankshares set a $80.00 price target on Revolution Medicines in a report on Friday, October 17th. UBS Group raised Revolution Medicines to a "strong-buy" rating in a research note on Thursday, December 4th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Revolution Medicines in a research report on Wednesday, October 8th. Finally, Royal Bank Of Canada began coverage on Revolution Medicines in a report on Monday, November 3rd. They issued an "outperform" rating and a $77.00 target price on the stock. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $78.50.
Get Our Latest Research Report on Revolution Medicines
Revolution Medicines Company Profile
(
Get Free Report)
Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
